G. Riess

发表

Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.

R. Kirsch, J. Kleim, R. Bender, 1994, Virology.

Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-did

E. De Clercq, J. Balzarini, M. Roesner, 1998, Biochemical pharmacology.

Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine.

E. De Clercq, J. Balzarini, M. Roesner, 1997, The Journal of infectious diseases.

R68.45, a plasmid with chromosome mobilizing ability (Cma) carries a tandem duplication.

A. Pühler, B. Holloway, G. Riess, 1980, Genetical research.

Preparation of carbocyclic phosphonate nucleosides

A. Müller, G. Riess, I. Winkler, 1992 .

Activity of Levofloxacin, Ofloxacin, D-Ofloxacin and Ciprofloxacin against Systemic and Respiratory Tract Infections in Laboratory Animals

G. Riess, A. Bryskier, G. Seibert, 2012, Drugs.

Heterologous expression of the alpha-amylase inhibitor gene cloned from an amplified genomic sequence of Streptomyces tendae

G. Riess, K. Koller, 1989, Journal of bacteriology.

Heterologous Expression of the oL-Amylase Inhibitor Gene Cloned

G. Riess, K. Koller, Hoechst, 2022 .

Spontaneous deletions of the chromosome-mobilizing plasmid R68.45 in Pseudomonas aeruginosa PAO.

D. Haas, G. Riess, 1983, Plasmid.

Relationship of group P1 plasmids revealed by heteroduplex experiments: RP1, RP4, R68 and RK2 are identical.

A. Pühler, G. Riess, H. Burkardt, 1979, Journal of general microbiology.

Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.

T. Merigan, M. Winters, J. Balzarini, 1999, The Journal of infectious diseases.

Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720

E. De Clercq, J. Balzarini, A. Karlsson, 1994, Journal of virology.

Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.

E. Arnold, R. Kirsch, Y. Hsiou, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication

Christoph, J. Kleim, R. Bender, 1993, Antimicrobial Agents and Chemotherapy.

Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.

G. Riess, P. Iyer, N. Klesel, 1995, The Journal of antimicrobial chemotherapy.

Resistance Pattern ofHumanImmunodeficiency VirusType1 Reverse Transcriptase toQuinoxaline S-2720

A. Karlsson, G. Riess, A. Paessens, 1994 .

Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors.

E. De Clercq, J. Balzarini, A. Karlsson, 1994, Biochemical and biophysical research communications.

In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.

R. Kirsch, J. Kleim, A. Paessens, 1997, Virology.

Proteolytic enzymes from recombinant Streptomyces lividans TK24.

G. Riess, W. Aretz, K. Koller, 1989, FEMS microbiology letters.

Recombinant Streptomyces Lividans Secretes a Fusion Protein of Tendamistat and Proinsulin

G. Riess, E. Uhlmann, H. Wallmeier, 1989, Nature Biotechnology.

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.

A. D. Clark, Jianping Ding, S. Hughes, 1998, Journal of molecular biology.

Inhibition of HIV-1 protease by short peptides derived from the terminal segments of the protease.

W. Schäfer, E. Jaeger, C. Meichsner, 1992, Biochemical and biophysical research communications.

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication

R. Kaiser, M. Wichers, R. Kirsch, 1995, Antimicrobial agents and chemotherapy.